The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years

Cancer

Volumn 104, Issue 4, 2005, Pages 825-832

  Korshunov, Andrey ^a   Sycheva, Regina ^a   Golanov, Andrey ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

Glioblastoma; Molecular analysis; Prognosis; Young adults

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; BRAIN TUMOR; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 9P; CHROMOSOME LOSS; COHORT ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGE FACTORS; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; FEMALE; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROGNOSIS;

EID: 23444435222     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21221     Document Type: Article

References (33)

1. Macdonald DR. New frontiers in the treatment of malignant glioma. Semin Oncol. 2003;30:72-76.
2. Shaw GS. Nothing ventured, nothing gained: treatment of glioblastoma multiforme in the elderly. J Clin Oncol. 2004; 22:1540-1541.
3. Kleihues P, Cavenee WK, editors. Tumors of the nervous system, pathology and genetics: World Health Organization international classification of tumours. Lyon: IARC Press, 2000.
4. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol. 2004;6:227-235.
5. Lutterbach J, Saurbrei W, Guttenberg R. Multivariate analysis of prognostic factors in patients with glioblastomas. Strahlenther Onkol. 2003;179:8-15.
6. Ohgaki H, Dessen P, Iourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64:6892-6899.
7. Ichimura K, Ohgaki H, Kleihues P, Collins VP. Molecular pathogenesis of astrocytic tumors. J Neurooncol. 2004;70: 137-160.
8. Backlund LM, Nilsson BR, Hoike HM, et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild type PTEN. Clin Cancer Res. 2003;9:4151-4158.
9. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastomas. Clin Cancer Res. 2004;10:228-233.
10. Burton E, Lamborn KR, Feuerstein BG, et al. Genetic aberrations defined by comparative genome hybridization distinguish long-term from typical survivors in glioblastoma. Cancer Res. 2002;62:6205-6210.
11. Kamyrio T, Tada K, Shiraishi S, et al. Analysis of homozygous deletions of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg. 2002; 96:815-822.
12. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol. 2002;61:321-328.
13. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122-1128.
14. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1256.
15. Wiltshire RN, Herndon JE, Lloyd A, et al. Comparative genomic hybridization analysis of astrocytomas. Prognostic and diagnostic implications. J Mol Diagn. 2004;6:166-179.
16. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytoma and evaluation of prognostic significance. J Neuropathol Exp Neurol. 2004;63:700-707.
17. Fuller CE, Schmidt RE, Roth KA, et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol. 2003;62:1118-1128.
18. Fuller CE, Wang H, Zhang W, Fuller GN, Perry A. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J Neuropathol Exp Neurol. 2002; 61:1078-1084.
19. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells. The utility of fluorescence in situ hybridization. Clin Cancer Res. 2004;10:7820-7826.
20. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 2004;100:2318-2326.
21. Korshunov A, Golanov A, Sycheva R, Pronin I. Prognostic value of tumour-associated antigens immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol. 1999;52:574-580.
22. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol. 2001;60: 1099-1104.
23. Huncharek M, Kupelnik B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme. Results of a meta-analysis. Oncol Res. 2000;12: 107-112.
24. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962-6970.
25. Zhou YH, Tan F, Hess KR, Yung WKA. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003;9:3369-3375.
26. Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Clin Cancer Res. 1999;5:1435-1433.
27. Brat DJ, Seiferheld WF, Perry A, et al. Analysis of 1p, 19q, 9p and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group. Neuro-oncol. 2004;6:96-103.
28. Smith JS, Perry A, Borell TJ, et al. Alteration of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
29. Rickert CH, Paulus W. Comparative genomic hybridization in central and peripheral nervous system tumors of childhood and adolescence. J Neuropathol Exp Neurol. 2004;63: 399-417.
30. Mahler-Araujo MB, Sanoudou D, Tingby O, et al. Structural genomic abnormalities of chromosomes 9 and 18 in myxopapillary ependymomas. J Neuropathol Exp Neurol. 2003;62: 927-935.
31. Rajaram V, Leuthardt EC, Singh PK, et al. 9p21 and 13q14 dosages in ependymomas. A clinico-pathological studies of 101 cases. Mod Pathol. 2004;17:9-14.
32. Rickert CH, Wiestler OD, Paulus W. Chromosomal imbalances in choroid plexus tumors. Am J Pathol. 2002;160:1105-1113.
33. Rickert CH, Strater R, Kaatsch P, et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001;158:1525-1532.